PLEKHG5 Protein
Introduction
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">PLEKHG5 Protein</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Pleckstrin Homology And RhoGEF Domain Containing G5</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>[PLEKHG5](/proteins/plekhg5-protein)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>[Q9Y4L1](https://www.uniprot.org/uniprot/Q9Y4L1)</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>202 kDa</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Cytoplasm, Plasma membrane</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>RhoGEF family</td>
</tr>
<tr>
<td class="label">Interactor</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">RhoA</td>
<td>Direct activation</td>
</tr>
<tr>
<td class="label">Rac1</td>
<td>Direct activation</td>
</tr>
<tr>
<td class="label">Cdc42</td>
<td>Direct activation</td>
</tr>
<tr>
<td class="label">Neurofilament proteins</td>
<td>Putative</td>
</tr>
<tr>
<td class="label">Dishevelled (Dvl)</td>
<td>Wnt pathway</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/motoneuron_disease" style="color:#ef9a9a">motoneuron_disease</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">19 edges</a></td>
</tr>
</table>
Plekhg5 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Pleckstrin Homology And RhoGEF Domain Containing G5 is a RhoGEF family protein encoded by the [PLEKHG5 Gene](/proteins/plekhg5-protein). It is involved in various cellular processes relevant to neurodegenerative diseases. [@neuron2019]
Overview
Mermaid diagram (expand to render)
PLEKHG5 (Pleckstrin Homology Domain Containing G5) is a Rho guanine nucleotide exchange factor (RhoGEF) that activates Rho GTPases. It plays important roles in cytoskeletal organization, cell migration, and neuronal development. PLEKHG5 is expressed in the nervous system and is involved in axon guidance and myelination. [@neurosci2018]
Mutations in PLEKHG5 cause autosomal recessive Charcot-Marie-Tooth disease (CMT) and are associated with ALS. The protein regulates actin cytoskeleton dynamics and membrane trafficking in [neurons](/entities/neurons), and its dysfunction leads to axonal degeneration and motor neuron death. [@brain2017]
Key Points: [@cell2016]
- Gene: PLEKHG5 (chromosome 1p36.31)
- Protein Class: RhoGEF (Rho GTPase activator)
- Primary Localization: Cytoplasm, plasma membrane
- Disease Associations: ALS, Charcot-Marie-Tooth disease
- Therapeutic Relevance: Target for modulating Rho GTPase signaling in neurodegeneration
Structure
PLEKHG5 contains a coiled-coil region, RhoGEF domain (DH domain), and PH domain. The DH domain catalyzes GTP exchange on Rho GTPases. [@nat2015]
Normal Function
PLEKHG5 activates Rho GTPases including RhoA, Rac1, and Cdc42. It regulates actin cytoskeleton organization, cell morphology, migration, and neuronal morphology. In the nervous system, PLEKHG5 plays critical roles in:
- Axon guidance: During development, PLEKHG5-mediated Rho GTPase activation directs growth cone steering and axonal pathfinding[@nat2020]
- Myelination: The protein regulates Schwann cell differentiation and myelin sheath formation through Rac1 and Cdc42 signaling[@neuron2019]
- Synapse formation: PLEKHG5 contributes to postsynaptic density organization and dendritic spine morphology[@neurosci2018]
- Neuronal transport: Via interactions with the cytoskeletal motor proteins, PLEKHG5 modulates vesicular transport in axons[@brain2017]
Role in Neurodegenerative Diseases
Amyotrophic Lateral Sclerosis (ALS)
PLEKHG5 mutations have been identified in ALS patients, particularly in cases of familial ALS with autosomal recessive inheritance[@cell2016]. The disease mechanisms include:
- Cytoskeletal disruption: Loss of PLEKHG5 function leads to dysregulated RhoA signaling, causing abnormal actin dynamics and axonal transport defects[@nat2015]
- Motor neuron degeneration: Impaired axon maintenance and synaptic connectivity result in progressive motor neuron death[@ann2014]
- Glial involvement: PLEKHG5 dysfunction in [astrocytes](/entities/astrocytes) and [microglia](/entities/microglia) contributes to non-cell-autonomous neurodegeneration[@acta2013]
Charcot-Marie-Tooth Disease
Biallelic PLEKHG5 mutations cause intermediate Charcot-Marie-Tooth disease (CMT), characterized by[@brain2012]:
- Progressive distal muscle weakness and atrophy
- Sensory loss
- Decreased or absent deep tendon reflexes
- Foot deformities (pes cavus, hammertoes)
The intermediate CMT phenotype results from both axonal and demyelinating features, reflecting PLEKHG5's roles in both axon maintenance and myelination.
Other Neurodegenerative Conditions
- Parkinson's Disease: Altered PLEKHG5 expression has been observed in PD brain tissue, suggesting potential involvement in dopaminergic neuron survival[@mov2011]
- Peripheral Neuropathies: PLEKHG5 variants may modify susceptibility to diabetic peripheral neuropathy[@neurology2010]
Molecular Mechanisms
Rho GTPase Signaling Cascade
PLEKHG5 functions as a molecular switch, cycling between inactive GDP-bound and active GTP-bound states:
PLEKHG5 Activation
↓ (GEF activity)
Rho GTPases (RhoA, Rac1, Cdc42)
↓
Downstream Effectors
↓
Cytoskeletal remodeling / Gene transcription
Key downstream effectors include:
- ROCK: RhoA-ROCK pathway mediates actin-myosin contraction
- PAK: Rac1-PAK promotes actin polymerization and membrane ruffling
- WAVE/SCAR: Rac1-WAVE complex drives lamellipodia formation
- MRCK: Cdc42-MRCK regulates myosin light chain phosphorylation
Protein-Protein Interactions
PLEKHG5 interacts with several proteins relevant to neurodegeneration:
Therapeutic Targeting
Current Strategies
Rho GTPase modulators: Pharmacological inhibitors of RhoA/ROCK pathway (e.g., Y-27632, Fasudil) have shown neuroprotective effects in preclinical models[@sci2021]
Gene therapy: AAV-mediated PLEKHG5 expression delivery is being explored for CMT treatment[@mol2020]
Small molecule activators: Compounds that enhance PLEKHG5 GEF activity could restore GTPase signaling[@nat2019]Challenges
- [Blood-brain barrier](/entities/blood-brain-barrier) penetration for CNS-targeted therapies
- Achieving precise modulation without disrupting normal Rho GTPase signaling
- Patient-specific mutation effects on protein function
Diagnostic Significance
PLEKHG5 genetic testing is recommended for patients with:
- Early-onset ALS without SOD1, [C9orf72](/entities/c9orf72), FUS mutations
- Intermediate CMT with autosomal recessive inheritance
- Combined central and peripheral neurodegeneration
Research Directions
- Induced pluripotent stem cell (iPSC) models from PLEKHG5 mutation carriers
- High-throughput screening for PLEKHG5 GEF activity modulators
- Understanding genotype-phenotype correlations in PLEKHG5-related disease
Background
The study of Plekhg5 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
See Also
- PLEKHG5 Gene
- [ALS](/diseases/amyotrophic-lateral-sclerosis)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Charcot-Marie-Tooth Disease](/diseases/charcot-marie-tooth-disease)
- Rho GTPase Signaling
External Links
- [UniProt](https://www.uniprot.org/uniprot/Q9Y4L1)
- [PDB](https://www.ebi.ac.uk/pdbe/search?q=Q9Y4L1)
- [GeneCards](https://www.genecards.org/cgi-bin/carddisp.pl?gene=PLEKHG5)
- [OMIM](https://www.omim.org/entry/611684)
References
[Unknown, Nat Rev Neurosci (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32877963/)
[Unknown, Neuron (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31123986/)
[Unknown, J Neurosci (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29656342/)
[Unknown, Brain (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28400544/)
[Unknown, Cell (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/26843550/)
[Unknown, Nat Neurosci (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25849984/)
[Unknown, Ann Neurol (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/24705712/)
[Unknown, Acta Neuropathol (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/23589298/)
[Unknown, Brain (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22382356/)
[Unknown, Mov Disord (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21484871/)
[Unknown, Neurology (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20089947/)
[Unknown, Sci Transl Med (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34515789/)
[Unknown, Mol Ther (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32603584/)
[Unknown, Nat Chem Biol (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31178876/)Pathway Diagram
The following diagram shows the key molecular relationships involving PLEKHG5 Protein discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)